Statement Of Cash Flows [Abstract]

Egetis Therapeutics - Filing #676549

Concept 2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operations before changes in working capital
3,093,000,000 SEK
1,844,000,000 SEK
Adjustments for increase (decrease) in trade and other payables
538,000,000 SEK
216,000,000 SEK
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents
0 SEK
0 SEK
Cash flows from (used in) financing activities [abstract]
Payments for share issue costs
263,000,000 SEK
126,000,000 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.